Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Pancreatic Cancer, Small-Cell Lung Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Atopic Dermatitis (Atopic Eczema), Breast Cancer, Colon Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vascular Dementias and Vulvar Cancer.
The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook